非小细胞肺癌的联合免疫治疗现状  

Current status of combined immunotherapy for non-small cell lung cancer

作　　者：杨圣杰 管燕[2] 马晓 张佳慧 郭其森[2] YANG Shengjie;GUAN Yan;MA Xiao;ZHANG Jiahui;GUO Qisen(School of Medicine and Life Sciences,University of Jinan Shandong Academy of Medical Sciences,Shandong Jinan 250200,China;Academy of Medical Sciences,Shandong Tumor Hospital,Shandong Jinan 250117,China)

机构地区：[1]济南大学山东省医学科学院医学与生命科学学院,山东济南250200 [2]山东省肿瘤医院,山东省医学科学院,山东济南250117

出　　处：《现代肿瘤医学》2021年第10期1813-1816,共4页Journal of Modern Oncology

摘　　要：对于晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的患者来说,化疗、放疗、靶向治疗及抗血管生成治疗虽然可以改善其预后,但经相关研究发现,NSCLC患者的5年生存率仍不尽人意。近年来以程序性死亡蛋白1(programmed cell death protein 1,PD-1)/程序性死亡蛋白配体1(programmed death-ligand 1,PD-L1)抑制剂为代表免疫检查点抑制剂的出现为晚期NSCLC患者的治疗带来了新的希望。探索免疫检查点抑制剂联合化疗、抗血管生成药物、放疗的各项治疗策略是目前肿瘤界的热门话题,本文将对NSCLC联合免疫治疗的现状进行总结与讨论。For patients with advanced non-small cell lung cancer(NSCLC),chemotherapy,radiotherapy,targeted therapy and anti-angiogenesis therapy can improve their prognosis,but the 5-year survival rate of NSCLC patients is still unsatisfactory.In recent years,the emergence of programmed cell death protein 1(PD1)/programmed death ligand 1(PD-L1)inhibitors as the representative of immunological checkpoint inhibitors has brought new hope for advanced NSCLC patients.Exploring the strategies of immuno-checkpoint inhibitors combined with chemotherapy,anti-angiogenesis drugs and radiotherapy is a hot topic in the field of cancer at present.This review will summarize and discuss the current situation of NSCLC combined with immunotherapy.

关 键 词：非小细胞肺癌 免疫检查点抑制剂 PD-1/PD-L1抑制剂 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]